Top

Published in:

Open Access 06-03-2024 | Acute Myeloid Leukemia | Review Article

Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification

Authors: Synne D. Rørvik, Synne Torkildsen, Øystein Bruserud, Tor Henrik Anderson Tvedt

Published in: Annals of Hematology | Issue 4/2024

Abstract

Two different systems exist for subclassification of acute myeloid leukemia (AML); the World Health Organization (WHO) Classification and the International Consensus Classification (ICC) of myeloid malignancies. The two systems differ in their classification of AML defined by recurrent chromosomal abnormalities. One difference is that the ICC classification defines an AML subset that includes 12 different genetic abnormalities that occur in less than 4% of AML patients. These subtypes exhibit distinct clinical traits and are associated with treatment outcomes, but detailed description of these entities is not easily available and is not described in detail even in the ICC. We searched in the PubMed database to identify scientific publications describing AML patients with the recurrent chromosomal abnormalities/translocations included in this ICC defined patient subset. This patient subset includes AML with t(1;3)(p36.3;q21.3), t(3;5)(q25.3;q35.1), t(8;16)(p11.2;p13.3), t(1;22)(p13.3;q13.1), t(5;11)(q35.2;p15.4), t(11;12)(p15.4;p13.3) (involving NUP98), translocation involving NUP98 and other partner, t(7;12)(q36.3;p13.2), t(10;11)(p12.3;q14.2), t(16;21)(p11.2;q22.2), inv(16)(p13.3q24.3) and t(16;21)(q24.3;q22.1). In this updated review we describe the available information with regard to frequency, biological functions of the involved genes and the fusion proteins, morphology/immunophenotype, required diagnostic procedures, clinical characteristics (including age distribution) and prognostic impact for each of these 12 genetic abnormalities.

Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36(7):1703–1719PubMedPubMedCentral

Arber DA, Orazi A, Hasserjian RP et al (2022) International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200–1228PubMedPubMedCentral

Gough SM, Slape CI, Aplan PD (2011) NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 118(24):6247–6257PubMedPubMedCentral

Michmerhuizen NL, Klco JM, Mullighan CG (2020) Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood 136(20):2275–2289PubMedPubMedCentral

Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST et al (2011) NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 118(13):3645–3656PubMed

Mohanty S (2023) NUP98 rearrangements in AML: Molecular mechanisms and clinical implications. Onco 3(3):147–164

Thol F, Kölking B, Hollink IHI et al (2013) Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. Leukemia 2013/03/01(3):750–754

Xie W, Hu S, Xu J et al (2019) Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. Ann Hematol 98(5):1149–1157PubMed

Quessada J, Cuccuini W, Saultier P et al (2021) Cytogenetics of Pediatric Acute myeloid leukemia: a review of the current knowledge. Genes 12(6):924PubMedPubMedCentral

10.

Marceau-Renaut A, Duployez N, Ducourneau B et al (2018) Molecular profiling defines distinct prognostic subgroups in Childhood AML: a Report from the French ELAM02 Study Group. HemaSphere 2(1):e31PubMedPubMedCentral

11.

Bolouri H, Farrar JE, Triche T Jr. et al (2018) The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 24(1):103–112PubMed

12.

Struski S, Lagarde S, Bories P et al (2017) NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia 31(3):565–572PubMed

13.

Niktoreh N, Walter C, Zimmermann M et al (2019) Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in various combinations define a Poor Prognostic Group in Pediatric Acute myeloid leukemia. J Oncol 2019:1609128PubMedPubMedCentral

14.

Shiba N, Ichikawa H, Taki T et al (2013) NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer 52(7):683–693PubMed

15.

Bertrums EJM, Smith JL, Harmon L et al (2023) Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica 02(23):2044–2058

16.

Romana SP, Radford-Weiss I, Ben Abdelali R et al (2006) NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone De Cytogénétique Hématologique. Leukemia 20(4):696–706PubMed

17.

Jaju RJ, Haas OA, Neat M et al (1999) A new recurrent translocation, t(5;11)(q35;p15.5), associated with Del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG). Blood 94(2):773–780PubMed

18.

Hara Y, Shiba N, Ohki K et al (2017) Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-down syndrome. Genes Chromosom Cancer 56(5):394–404PubMed

19.

de Rooij JDE, Hollink IHIM, Arentsen-Peters STCJM et al (2013) NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 27(12):2280–2288 2013/12/01PubMed

20.

Tao S, Song L, Deng Y et al (2020) Acute myeloid leukemia with NUP98-RARG Gene Fusion similar to Acute Promyelocytic Leukemia: Case Report and Literature Review. Onco Targets Ther 13:10559–10566PubMedPubMedCentral

21.

Zhu HH, Yang MC, Wang F et al (2020) Identification of a novel NUP98-RARA fusion transcript as the 14th variant of acute promyelocytic leukemia. Am J Hematol 95(7):E184–e186PubMed

22.

Ostronoff F, Othus M, Gerbing RB et al (2014) NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood 124(15):2400–2407PubMedPubMedCentral

23.

de Rooij JD, Hollink IH, Arentsen-Peters ST et al (2013) NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 27(12):2280–2288PubMed

24.

Hara Y, Shiba N, Ohki K et al (2017) Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-down syndrome. Genes Chromosomes Cancer 56(5):394–404PubMed

25.

Gruber TA, Larson Gedman A, Zhang J et al (2012) An inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 22(5):683–697PubMedPubMedCentral

26.

Masetti R, Bertuccio SN, Pession A, Locatelli F (2019) CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol 184(3):337–347PubMed

27.

Noort S, Zimmermann M, Reinhardt D et al (2018) Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. Blood 132(15):1584–1592PubMedPubMedCentral

28.

Zerkalenkova E, Panfyorova A, Kazakova A et al (2018) Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG. Ann Hematol 97(6):977–988PubMed

29.

Eidenschink Brodersen L, Alonzo TA, Menssen AJ et al (2016) A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from children’s Oncology Group. Leukemia 30(10):2077–2080PubMed

30.

Liu H, Wang SA, Schlette EJ et al (2018) Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1. Ann Hematol 97(10):1775–1783PubMed

31.

Kitabayashi I, Aikawa Y, Nguyen LA et al (2001) Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J 20(24):7184–7196PubMedPubMedCentral

32.

Yang XJ, Seto E (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37):5310–5318PubMed

33.

Chan EM, Chan RJ, Comer EM et al (2007) MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters. Exp Hematol 35(12):1782–1792PubMed

34.

Camos M, Esteve J, Jares P et al (2006) Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 66(14):6947–6954PubMed

35.

Diab A, Zickl L, Abdel-Wahab O et al (2013) Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res 37(1):32–36PubMed

36.

Vo N, Goodman RH (2001) CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 276(17):13505–13508PubMed

37.

Blobel GA (2000) CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95(3):745–755PubMed

38.

Chen J, Odenike O, Rowley JD (2010) Leukaemogenesis: more than mutant genes. Nat Rev Cancer 10(1):23–36PubMedPubMedCentral

39.

Gervais C, Murati A, Helias C et al (2008) Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogenetique hematologique. Leukemia 22(8):1567–1575PubMed

40.

Haferlach T, Kohlmann A, Klein HU et al (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23(5):934–943PubMed

41.

Hanslip JI, Swansbury GJ, Pinkerton R, Catovsky D The translocation t(8;16)(p11;p13) defines an AML subtype with distinct cytology and clinical features. Leukemia & Lymphoma. 1992 1992/01/01;6(6):479–486

42.

Heim S, Mitelman F, Chichester (2015) West Sussex: John Wiley & Sons, Inc. Chichester, West Sussex

43.

Kayser S, Hills RK, Langova R et al (2021) Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. Br J Haematol 192(5):832–842PubMed

44.

Coenen EA, Zwaan CM, Reinhardt D et al (2013) Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood 122(15):2704–2713PubMedPubMedCentral

45.

Borel C, Huynh A, Chaufour X et al (2010) Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. Leuk Res 34(4):e88–90PubMed

46.

Caudell D, Aplan PD (2008) The role of CALM-AF10 gene fusion in acute leukemia. Leukemia 22(4):678–685PubMed

47.

Archangelo LF, Glasner J, Krause A, Bohlander SK (2006) The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10. Oncogene 25(29):4099–4109PubMed

48.

Dik WA, Brahim W, Braun C et al (2005) CALM-AF10 + T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia 19(11):1948–1957PubMed

49.

DiNardo CD, Tang G, Pemmaraju N et al (2015) Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. Clin Lymphoma Myeloma Leuk 15(1):47–51PubMed

50.

Mark C, Kolb EA, Goemans BF et al (2022) Treatment outcomes of Childhood Picalm:MLLT10 + Acute Leukemias: An International Retrospective Study. Blood 140(Supplement 1):3403–3404

51.

Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365PubMed

52.

Bacher U, Kern W, Schnittger S et al (2005) Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 90(11):1502–1510PubMed

53.

Savage NM, Kota V, Manaloor EJ et al (2010) Acute leukemia with PICALM-MLLT10 fusion gene: diagnostic and treatment struggle. Cancer Genet Cytogenet 202(2):129–132PubMed

54.

Park M-S, Kim H-Y, Lee JJ et al (2023) The First Case of Acute myeloid leukemia with t(10;11)(p13;q21); PICALM-MLLT10 rearrangement presenting with extensive skin involvement. Annals Lab Med 43(3):310–314

55.

Borel C, Dastugue N, Cances-Lauwers V et al (2012) PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk Res 36(11):1365–1369PubMed

56.

La Starza R, Crescenzi B, Krause A et al (2006) Dual-color split signal fluorescence in situ hybridization assays for the detection of CALM/AF10 in t(10;11)(p13;q14-q21)-positive acute leukemia. Haematologica 91(9):1248–1251PubMed

57.

Dreyling MH, Schrader K, Fonatsch C et al (1998) MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood 91(12):4662–4667PubMed

58.

Grossmann V, Bacher U, Kohlmann A et al (2012) EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia. Br J Haematol 157(3):387–390PubMed

59.

Ou DM, Liu GX, Yan JY (2004) [CALM-AF10 fusion transcripts in primary leukemia with t(10;11) and in vitro chemotherapy sensitivity of leukemic cells with t(10;11)]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12(6):770–773PubMed

60.

Sarkaria SM, Christopher MJ, Klco JM, Ley TJ (2014) Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia 28(12):2403–2406PubMedPubMedCentral

61.

Carroll A, Civin C, Schneider N et al (1991) The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood 78(3):748–752PubMed

62.

Mercher T, Raffel GD, Moore SA et al (2009) The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 119(4):852–864PubMedPubMedCentral

63.

Chisholm KM, Smith J, Heerema-McKenney AE et al (2023) Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: a report from the Children’s Oncology Group. Pediatr Blood Cancer 70(5):e30251PubMed

64.

Saito Y, Makita S, Chinen S et al (2020) Acute megakaryoblastic leukaemia with t(1;22)(p13·3;q13·1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour. Br J Haematol 190(6):e329–e332PubMed

65.

Hsiao H-H, Yang M-Y, Liu Y-C et al (2005) RBM15-MKL1 (OTT-MAL) fusion transcript in an adult acute myeloid leukemia patient. Am J Hematol 79(1):43–45PubMed

66.

de Rooij JD, Masetti R, van den Heuvel-Eibrink MM et al (2016) Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood 127(26):3424–3430PubMedPubMedCentral

67.

Lion T, Haas OA, Harbott J et al (1992) The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood 79(12):3325–3330PubMed

68.

Dastugue N, Lafage-Pochitaloff M, Pagès M-P et al (2002) Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français De Cytogénétique Hématologique (GFCH). Blood 100(2):618–626PubMed

69.

Marques-Piubelli ML, Cordeiro MG, Cristofani L et al (2020) Acute megakaryoblastic leukemia with t(1;22)(p13.3;q13.1); RBM15-MKL1 mimicking hepatoblastoma in an infant: the role of karyotype in differential diagnosis. Pediatr Blood Cancer 67(3):e28111PubMed

70.

Brouwer N, Matarraz S, Nierkens S et al (2022) Immunophenotypic analysis of Acute Megakaryoblastic Leukemia: a EuroFlow Study. Cancers (Basel). ;14(6)

71.

Lim G, Choi JR, Kim MJ et al (2010) Detection of t(3;5) and NPM1/MLF1 rearrangement in an elderly patient with acute myeloid leukemia: clinical and laboratory study with review of the literature. Cancer Genet Cytogenet 199(2):101–109PubMed

72.

Dumézy F, Renneville A, Mayeur-Rousse C et al (2013) Acute myeloid leukemia with translocation t(3;5): new molecular insights. Haematologica 98(4):e52–e54PubMedPubMedCentral

73.

Aypar U, Knudson RA, Pearce KE et al (2014) Development of an NPM1/MLF1 D-FISH probe set for the detection of t(3;5)(q25;q35) identified in patients with acute myeloid leukemia. J Mol Diagn 16(5):527–532PubMed

74.

Alattar ML, Kantarjian HM, Cortes JE et al (2012) Incidence and outcomes of a rare translocation t(3,5) in patients (pts) with Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 120(21):1456–1456

75.

Tosi S, Harbott J, Teigler-Schlegel A et al (2000) T(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer 29(4):325–332PubMed

76.

Park J, Kim M, Lim J et al (2009) Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): the incidence and correlation of a HLXB9 overexpression. Cancer Genet Cytogenet 191(2):102–105PubMed

77.

von Bergh AR, van Drunen E, van Wering ER et al (2006) High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer 45(8):731–739

78.

Ballabio E, Cantarella CD, Federico C et al (2009) Ectopic expression of the HLXB9 gene is associated with an altered nuclear position in t(7;12) leukaemias. Leukemia 23(6):1179–1182PubMed

79.

Ragusa D, Dijkhuis L, Pina C, Tosi S (2023) Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets. Biosci Rep. ;43(1)

80.

Waraky A, Östlund A, Arabanian L et al (2019) The translocation t(7;12)(q36;p13) induces myeloid leukemia in Immuno-compromised but not immunocompetent mice. Blood 134(Supplement1):2707–2707

81.

Slater RM, von Drunen E, Kroes WG et al (2001) T(7;12)(q36;p13) and t(7;12)(q32;p13)--translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 15(6):915–920PubMed

82.

Espersen ADL, Noren-Nyström U, Abrahamsson J et al (2018) Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: data from Nordic Society for Pediatric Hematology and Oncology (NOPHO-AML) and review of the literature. Genes Chromosomes Cancer 57(7):359–365PubMed

83.

Taketani T, Taki T, Sako M et al (2008) MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines. Cancer Genet Cytogenet 186(2):115–119PubMed

84.

Shimizu S, Suzukawa K, Kodera T et al (2000) Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21). Genes Chromosomes Cancer 27(3):229–238PubMed

85.

Sato Y, Murai M, Tsunoda J et al (1991) Second relapse of acute promyelocytic leukemia (ANLL-M3) with t(15;17) and t(1;3)(p36;q21). Cancer Genet Cytogenet 57(1):53–58PubMed

86.

Milton JM, Garson OM, Paton CM, Hurley TF (1984) A complicated but nonrandom karyotype in preleukemia. Cancer Genet Cytogenet 13(1):37–41PubMed

87.

Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390PubMedPubMedCentral

88.

Mochizuki N, Shimizu S, Nagasawa T et al (2000) A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96(9):3209–3214PubMed

89.

Lahortiga I, Agirre X, Belloni E et al (2004) Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene 23(1):311–316PubMed

90.

Nishikata I, Sasaki H, Iga M et al (2003) A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood 102(9):3323–3332PubMed

91.

Xiao Z, Zhang M, Liu X et al (2006) MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Leuk Res 30(3):332–334PubMed

92.

Lim G, Kim MJ, Oh SH et al (2010) Acute myeloid leukemia associated with t(1;3)(p36;q21) and extreme thrombocytosis: a clinical study with literature review. Cancer Genet Cytogenet 203(2):187–192PubMed

93.

Welborn JL, Lewis JP, Jenks H, Walling P (1987) Diagnostic and prognostic significance of t(1;3)(p36;q21) in the disorders of hematopoiesis. Cancer Genet Cytogenet 28(2):277–285PubMed

94.

Block AW, Carroll AJ, Hagemeijer A et al (2002) Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 33(4):401–412PubMed

95.

Charrin C, Belhabri A, Treille-Ritouet D et al (2002) Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features. Hematol J 3(1):21–31PubMed

96.

Mauritzson N, Albin M, Rylander L et al (2002) Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 16(12):2366–2378PubMed

97.

Duhoux FP, Ameye G, Montano-Almendras CP et al (2012) PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. Br J Haematol 156(1):76–88PubMed

98.

Eveillard M, Delaunay J, Richebourg S et al (2015) The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. Haematologica 100(3):e114–e115PubMedPubMedCentral

99.

Moir DJ, Jones PA, Pearson J et al (1984) A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders. Blood 64(2):553–555PubMed

100.

Secker-Walker LM, Mehta A, Bain B (1995) Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 91(2):490–501PubMed

101.

Bloomfield CD, Garson OM, Volin L et al (1985) T(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic-clinicopathologic association. Blood 66(6):1409–1413PubMed

102.

Chaudhury SS, Morison JK, Gibson BE, Keeshan K (2015) Insights into cell ontogeny, age, and acute myeloid leukemia. Exp Hematol 43(9):745–755PubMed

103.

de Rooij JD, Branstetter C, Ma J et al (2017) Pediatric non-down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet 49(3):451–456PubMedPubMedCentral

104.

Shiba N, Yoshida K, Shiraishi Y et al (2016) Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Br J Haematol 175(3):476–489PubMed

105.

Creutzig U, van den Heuvel-Eibrink MM, Gibson B et al (2012) Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120(16):3187–3205PubMed

106.

Niewerth D, Creutzig U, Bierings MB, Kaspers GJ (2010) A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116(13):2205–2214PubMed

107.

Tarlock K, Sulis ML, Chewning JH et al (2022) Hematopoietic cell transplantation in the treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic syndromes: guidelines from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy. 28(9):530–545

108.

Lee NH, Choi YB, Yi ES et al (2016) Monosomal karyotype is not a predictor of dismal outcome in childhood de novo acute myeloid leukemia. Leuk Res 50:57–62PubMed

109.

Boils CL, Mohamed AN (2008) T(16;21)(q24;q22) in acute myeloid leukemia: case report and review of the literature. Acta Haematol 119(2):65–68PubMed

110.

Crisci S, Pota E, Iaccarino G et al (2020) Childhood therapy-related Acute myeloid leukemia with t(16;21)(q24;q22)/RUNX1-CBFA2T3 after a primitive neuroectodermal tumor of the Chest Wall. Clin Lymphoma Myeloma Leuk 20(10):e660–e666PubMed

111.

Calvo C, Fenneteau O, Leverger G et al (2021) Infant Acute myeloid leukemia: a Unique Clinical and Biological Entity. Cancers (Basel). ;13(4)

112.

Pine SR, Guo Q, Yin C et al (2007) Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 110(6):2128–2131PubMed

113.

Ford AM, Ridge SA, Cabrera ME et al (1993) In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363(6427):358–360ADSPubMed

114.

Gale KB, Ford AM, Repp R et al (1997) Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 94(25):13950–13954ADSPubMedPubMedCentral

115.

Klco JM, Mullighan CG (2021) Advances in germline predisposition to acute leukaemias and myeloid neoplasms. Nat Rev Cancer 21(2):122–137PubMed

116.

Antony-Debré I, Duployez N, Bucci M et al (2016) Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia 30(4):999–1002PubMed

117.

Sébert M, Passet M, Raimbault A et al (2019) Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood 134(17):1441–1444PubMed

118.

Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in Pediatric Cancer. N Engl J Med 373(24):2336–2346PubMedPubMedCentral

119.

Wu A, Liu Y, Wei S et al (2023) Clinical features of patients with acute myeloid leukaemia and the NUP98::NSD1 fusion gene. Int J Lab Hematol 45(4):589–591PubMed

120.

Noort S, Wander P, Alonzo TA et al (2021) The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica 106(2):630–634PubMed

121.

De Braekeleer E, Douet-Guilbert N, Morel F et al (2011) RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol 7(1):77–91PubMed

122.

Masetti R, Pigazzi M, Togni M et al (2013) CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood 121(17):3469–3472PubMed

123.

Masetti R, Rondelli R, Fagioli F et al (2014) Infants with acute myeloid leukemia treated according to the Associazione Italiana Di Ematologia E Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica 99(8):e127–e129PubMedPubMedCentral

124.

Park IJ, Park JE, Kim HJ et al (2010) Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature. Cancer Genet Cytogenet 196(1):105–108PubMed

125.

Toda Y, Nagai Y, Shimomura D et al (2017) Acute basophilic leukemia associated with the t(16;21)(p11;q22)/FUS-ERG fusion gene. Clin Case Rep 5(12):1938–1944PubMedPubMedCentral

126.

Saucedo-Campos A, Islas-Perez A, Lopez-Martinez B et al (2020) Acute myeloid leukemia associated with t(16:21)(p11;q22) in a pediatric patient. Bol Med Hosp Infant Mex 77(6):327–330PubMed

127.

Shikami M, Miwa H, Nishii K et al (1999) Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor alpha chain. Br J Haematol 105(3):711–719PubMed

Title: Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification
Authors: Synne D. Rørvik
Synne Torkildsen
Øystein Bruserud
Tor Henrik Anderson Tvedt
Publication date: 06-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Acute Myeloid Leukemia
Chromosomal Abnormality
Leukemia
Published in: Annals of Hematology / Issue 4/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05680-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2024

Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study

Can novel methods replace the gold standard chimerism method after allogeneic hematopoietic stem cell transplantation?

Intramedullary leukocytoclastic vasculitis and neutrophil extracellular trap (NET) formation in POEMS syndrome

Radiation hazards of the Ukraine nuclear power plants: how can international blood and marrow stem cell transplant societies help?

Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia

The role of TMPRSS6 gene polymorphism in iron resistance iron deficiency anaemia (IRIDA): a systematic review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials